HRH3 and colon adenocarcinoma: As shown in Figure 2A, the mean MCM2-positive indices of colonic adenocarcinomas in groups 3 (p < 0.001) and 4 (p < 0.001) were significantly lower than that of group 1, indicating that dietary administration with Hrh2 and Hrh3 antagonists decreased cancer cell proliferation.